Stock Short Interest Filing: CANNABIS SCIENCE INCORPORATED (OTCMKTS:CBIS) Has Increase in Shorts

November 28, 2016 - By Ellis Scott   ·   0 Comments

Stock Short Interest Filing: CANNABIS SCIENCE INCORPORATED (OTCMKTS:CBIS) Has Increase in Shorts

The stock of CANNABIS SCIENCE INCORPORATED (OTCMKTS:CBIS) registered an increase of 548.23% in short interest. CBIS’s total short interest was 1.34 million shares in November as published by FINRA. Its up 548.23% from 206,100 shares, reported previously. About 25.01 million shares traded hands. Cannabis Science Inc (OTCMKTS:CBIS) has risen 105.56% since April 25, 2016 and is uptrending. It has outperformed by 99.54% the S&P500.

Cannabis Science, Inc. is engaged in medical marijuana research and development. The company has a market cap of $94.36 million. The Firm works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid pharmaceutical products. It has a 0.77 P/E ratio. The Firm is involved in the creation of cannabis medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Insitutional Activity: The institutional sentiment increased to 1 in 2016 Q2. Its up 1.00, from 0 in 2016Q1. The ratio improved, as 1 funds sold all Cannabis Science Inc shares owned while 0 reduced positions. 1 funds bought stakes while 0 increased positions. They now own 308,179 shares or 1.58% more from 303,399 shares in 2016Q1.
Donaldson Lc accumulated 0% or 49,780 shares. Moreover, Stonebridge Capital Advsr Limited Liability Com has 0% invested in Cannabis Science Inc (OTCMKTS:CBIS) for 10,000 shares. Frontier Inv Mgmt accumulated 0% or 20,000 shares. Neville Rodie Shaw holds 0% of its portfolio in Cannabis Science Inc (OTCMKTS:CBIS) for 219,999 shares. Massmutual Trust Fsb Adv, a Connecticut-based fund reported 8,400 shares.

CBIS Company Profile

Cannabis Science, Inc., incorporated on May 4, 2007, is engaged in medical marijuana research and development. The Firm works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid pharmaceutical products. The Firm is involved in the creation of cannabis medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ellis Scott

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>